This compound is an Fmoc-protected amino acid derivative featuring a terminal alkene and a chiral center. It is primarily used as a building block in solid-phase peptide synthesis and pharmaceutical intermediate manufacturing.
Alcance del contenido: La información de esta página se refiere a la identificación química y a los contextos de suministro industrial, investigación y producción. No constituye una afirmación terapéutica, un consejo médico ni instrucciones de uso de medicamentos.
¿Adquiriendo o suministrando este compuesto?
Publique su inventario o una solicitud de compra
CAS 288617-75-4
3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)propanoic acid
Fmoc-protected amino acid building block
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-6-(1,3-dioxoisoindolin-2-yl)hexanoic acid
Fmoc-protected amino acid building block
(2S)-6-azido-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)hexanoic acid
Fmoc-protected amino acid building block
Fmoc-4-(tert-butoxycarbonylmethoxy)-L-phenylalanine
Fmoc-protected amino acid building block
Diazepam N-oxide
Pharmaceutical intermediate for impurity synthesis
6,7-Dimethoxyquinazoline-2,4(1H,3H)-dione
pharmaceutical intermediate for alpha1-blockers
Lifitegrast Impurity 125
Pharmaceutical impurity reference standard
N-(5-((Diphenylphosphoryl)methyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide
Pharmaceutical intermediate
(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-methyldec-9-enoic acid
MADFVGMQNXRFAF-SANMLTNESA-N
C[C@](CCCCCCC=C)(C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13